SNY — Sanofi
Is SNY overbought or oversold? Here is the current MarketMoodz read.
Sanofi (SNY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $39.92. The rating moved from Neutral to Oversold on October 3, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$39.92
- Last changeMoved from Neutral to Oversold on October 3, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
See all oversold Healthcare stocks →
AI analysis
Sanofi (SNY) benefits from a diversified revenue base (vaccines, specialty and established medicines) and a pipeline with late‑stage rare‑disease and biologic assets that offer credible medium‑term growth levers. Defensive sector flows and large‑cap pharma status support near‑term stability. However, pricing pressure from ongoing payer negotiations, intensified competition in metabolic therapies, and standard clinical/regulatory execution risks create meaningful downside scenarios. Expected performance in the next 1–4 weeks is driven mainly by macro sentiment, supply‑chain stability, and any incremental pipeline or regulatory news.
Key factors
- Diversified business mix with vaccines, specialty pharma and established medicines providing stable cash flow and defensive exposure during risk‑off market phases
- Meaningful late‑stage and rare‑disease pipeline assets that could drive medium‑term revenue upside and support specialty pricing
- Strong commercial footprint and global scale supporting manufacturing, distribution and payer negotiations across multiple therapeutic areas
- Recent sector rotation into defensive healthcare suggests near‑term buyer interest for large-cap pharma names like Sanofi
- Prudent capital allocation history (dividends, targeted M&A) that supports shareholder returns and long‑term strategic repositioning
Risks
- Ongoing U.S. Medicare negotiation/IRA policy and international pricing pressure that could compress pricing and margins for high‑cost therapies
- Intensifying competition in metabolic/obesity/T2D space (GLP‑1 and amylin combos) that may erode market share in overlapping indications
- Clinical or regulatory setbacks for key pipeline programs which would materially affect growth expectations
- Supply‑chain disruptions or manufacturing quality issues affecting vaccine or biologics output
- Currency exposure and macro weakness in key markets could depress reported results and cash flows
- Geopolitical uncertainty and resulting safe‑haven flows could create short‑term volatility and lower liquidity
- Patent cliffs or generic erosion on legacy products reducing established revenue without timely replacement
Latest MarketMoodz coverage
- Sanofi's Nexviazyme Baby‑COMET Hits All Phase 3 Endpoints2026-06-30
- EU Antitrust Probe of Sanofi Over Flu Vaccine Claims2026-06-29
- EU Opens Antitrust Probe into Sanofi Over Flu Vaccine Claims2026-06-26
- EU Approves Sanofi MS Drug Cenrifki Despite FDA Rejection2026-06-23
- FDA Grants Accelerated OK for Sanofi's Tzield in Pediatric T1D2026-06-15
See today's live rating, score and targets
Members see the live hourly rating for SNY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.